In September 2014 Viralytics was able to report a 39% irPFS rate at six months (22 of 57 evaluable patients) and a one-year survival rate of 73% (33 of first 45 patients alive at one year).
At the same time as it reported and the 39% irPFS rate Viralytics was able to disclose a one-year survival rate of 73% (33 of first 45 patients alive at one year). In September 2014 Viralytics was able to report a 39% irPFS rate at six months (22 of 57 evaluable patients).
In September 2014 Viralytics was able to report a 39% irPFS rate at six months (22 of 57 evaluable patients). At the same time as it reported and the 39% irPFS rate Viralytics was able to disclose a one-year survival rate of 73% (33 of first 45 patients alive at one year).
In September 2014 Viralytics was able to report a 39% irPFS rate at six months (22 of 57 evaluable patients). At the same time as it reported and the 39% irPFS rate Viralytics was able to disclose a one-year survival rate of 73% (33 of first 45 patients alive at one year).